Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
11.8M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
7.9M
-
Shares change
-
+91.7K
-
Total reported value, excl. options
-
$9M
-
Value change
-
-$9.82K
-
Put/Call ratio
-
0.23
-
Number of buys
-
18
-
Number of sells
-
-17
-
Price
-
$1.14
Significant Holders of Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (HEPA) as of Q4 2021
49 filings reported holding HEPA - Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Hepion Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (HEPA) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.9M shares
of 11.8M outstanding shares and own 67.12% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.33M shares), BlackRock Inc. (1.62M shares), GEODE CAPITAL MANAGEMENT, LLC (658K shares), Ikarian Capital, LLC (553K shares), STATE STREET CORP (323K shares), Bank of New York Mellon Corp (158K shares), NORTHERN TRUST CORP (141K shares), TWO SIGMA ADVISERS, LP (107K shares), PVG ASSET MANAGEMENT CORP (100K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (88.7K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.